Back to list
Field Research LaBretta Gregory July 13, 2015 PSYCH/600 Deborah Wilkerson This research paper will discuss how Strattera product claim to enhance, and how the publishedLiterature say about the issues or concerns of Strattera. It will also discuss what the research willreveal about how the promote a healthy development in this area, and the benefits of the product.It will also, show evidence to support this claim. Strattera is a non-stimulant medication, and Strattera is also a non-stimulant medication for treatment of distractibility, impulsivity, and hyperactivity in children, teens, with ADHD/ADD. According to Larry Silver M.D., states that Strattera was advertised as the first non-stimulant medication for ADHD/ADD, but there are several non-stimulant medication for ADHD/ADD such as tri-cyclic antidepressants, which is also prescribe to treat attention-deficit/hyperactivitydisorder. Strattera is approved for children aged 6 years and older, and the safety and the effectiveness has not been established in patients less than six years of age (Larry Silver M.D. 2011). According to Food and Drug Administration (FDA), issue today is issuing a Public Health Advisory to alert the physicians of the reports of suicidal thinking in children who have beenassociated with taking Strattera, which is a approved drug to treat children with ADHD. According to the FDA, they directed Eli Lilly & Company, and the manufacturer of Strattera